Ranolazine Tablet

RANOROOT-500

Ranolazine 500 mg Tablets

Division: DIABGLYM

Composition

Each prolonged-release tablet contains:

Ranolazine IP — 500 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Prolonged-release oral tablet

Product Description

RANOROOT-500 contains Ranolazine 500 mg, an advanced anti-anginal medication formulated for the effective management of chronic stable angina and ischemic heart disease. Ranolazine improves myocardial efficiency and reduces anginal symptoms without causing significant changes in heart rate or blood pressure, making it a valuable option for patients with persistent angina despite conventional anti-anginal therapy.

Ranolazine is widely used in cardiology for patients with chronic coronary artery disease, recurrent angina, diabetes-associated ischemic heart disease, and patients requiring additional anti-anginal therapy. It helps reduce the frequency of angina episodes, improve exercise tolerance, decrease nitrate requirements, and enhance overall quality of life.

RANOROOT-500 is particularly beneficial for patients initiating Ranolazine therapy, those with chronic stable angina inadequately controlled with beta-blockers, calcium channel blockers, nitrates, or combination anti-anginal therapy, as well as patients who require symptom control without significant hemodynamic effects.

Technical Knowledge of Ranolazine

Ranolazine selectively inhibits the late inward sodium current (late INa) in ischemic myocardial cells. Excess intracellular sodium during myocardial ischemia leads to increased intracellular calcium through the sodium-calcium exchanger, resulting in impaired myocardial relaxation, increased wall tension, and elevated myocardial oxygen consumption.

By inhibiting the late sodium current, Ranolazine reduces intracellular calcium overload, improves diastolic relaxation, decreases left ventricular wall tension, reduces myocardial oxygen consumption, and enhances myocardial perfusion efficiency without significantly affecting heart rate or systemic blood pressure.

Mechanism of Action

Ranolazine inhibits the late inward sodium current in myocardial cells, reduces intracellular sodium accumulation, decreases calcium overload, improves diastolic relaxation, reduces myocardial wall tension, enhances myocardial efficiency, and decreases anginal symptoms.

Key Benefits

Reduces the frequency of angina attacks

Improves exercise tolerance

Enhances myocardial relaxation

Decreases myocardial oxygen consumption

Reduces nitrate requirements

Minimal effect on heart rate and blood pressure

Effective add-on therapy for chronic stable angina

Suitable for long-term anti-anginal management under medical supervision

Clinical Applications

RANOROOT-500 is commonly prescribed for chronic stable angina, chronic coronary artery disease, refractory angina, ischemic heart disease, diabetes-associated coronary artery disease, add-on anti-anginal therapy, and patients requiring symptom control despite conventional anti-anginal treatment.

Facts About Ranolazine

Ranolazine is a unique anti-anginal agent that works through a metabolic and cellular mechanism rather than primarily through hemodynamic effects. It has extensive clinical evidence supporting improvement in angina frequency, exercise capacity, and quality of life. Because it has minimal effects on heart rate and blood pressure, it is particularly useful in patients who cannot tolerate higher doses of conventional anti-anginal medications.

Key Facts

Advanced anti-anginal therapy

Ranolazine 500 mg prolonged-release formulation

Improves myocardial efficiency and diastolic relaxation

Reduces angina frequency and nitrate requirement

Minimal hemodynamic effects

Evidence-based chronic angina management

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

RANOROOT-500 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.

Why Choose RANOROOT-500 for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Ranolazine 500 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented prolonged-release formulation

Controlled-release tablet manufacturing technology

Blister and Alu-Alu packaging options

RANOROOT-500 from DIABGLYM combines advanced anti-anginal therapy, improved myocardial efficiency, evidence-based cardiovascular care, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and advanced Ranolazine formulation.